Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation
Vaccine, Volume 37, No. 3, Year 2019
Notification
URL copied to clipboard!
Description
Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3–6 months after HSCT, focuses on short-term immunogenicity while long-term immunogenicity is not well characterized. The current Dutch immunization schedule, which starts at 12 months post allo-HSCT, was developed as a result of concerns on the coverage of long-term immunogenicity in international guidelines. We recently encountered two cases of allo-HSCT recipients who developed invasive pneumococcal disease (IPD) despite adequate revaccinations, which led us to question the immunogenicity of pneumococcal vaccinations in this patient group, and whether the currently existing vaccination schedules are appropriate. We included allo-HSCT recipients, vaccinated from one year after transplantation, and tested antibody responses to pneumococcal vaccination. We also performed a systematic review. Antibody concentrations were measured in 42 of 103 (41%) patients, with a response rate of 85% to PCV13 and 62% to PPSV23-unique serotypes. In six relevant studies, protection rates varied between 64 and 98%. Antibody responses in early and late vaccination schedules were similar, but adequate antibody responses were maintained better after late vaccination. Therefore, we propose a vaccination schedule that combines the advantages of early and late vaccination. This new schedule has been introduced since March 2018 in the two academic hospitals in Amsterdam, The Netherlands. © 2018 Elsevier Ltd
Authors & Co-Authors
Langedijk, Annefleur C.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Zeerleder, Sacha Sergio
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Meijer, Ellen
Netherlands, Amsterdam
Amsterdam Umc - Vrije Universiteit Amsterdam
Hazenberg, Mette D.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Grobusch, Martín Peter
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Goorhuis, Abram
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Statistics
Citations: 9
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.1016/j.vaccine.2018.11.053
ISSN:
0264410X
Research Areas
Health System And Policy
Maternal And Child Health
Study Approach
Systematic review